Teva’s Generic Exclusivity For Pravachol Reinstated By Federal Judge
This article was originally published in The Pink Sheet Daily
D.C. court reverses FDA’s determination that Teva’s 180-day exclusivity was triggered by an earlier patent dispute between Bristol and Apotex.
You may also be interested in...
FDA tells Teva that the 180-day exclusivity period for three pravastatin doses expired in February. As a result, as many as six companies – including Teva – could be in a position to launch generic Pravachol when Bristol’s composition of matter patent expires in April 2006. Teva plans to sue FDA to reinstate its first-to-file exclusivity period.
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency